5-MAPB Stats & Data

• Dose guidance and durations for 5‑MAPB are primarily derived from collated user reports (few formal human data); Erowid lists oral 30–70 mg common, 60–120 mg strong, and 3–6 h total duration with ~12 h after‑effects. Treat all ranges as tentative and start low.

• Reagent test every sample. Typical reactions: Marquis purple/black/brown, Mecke dark brown/black/smoky gray, Mandelin dark purple/purple‑brown, Simons dark blue. Color tones vary by batch and reagent age; lab testing provides definitive ID.

• Significant batch‑to‑batch variability has been reported by experienced users; some ‘magic’ batches were far more potent than others. This increases overdose/side‑effect risk if dosing by memory.

• Hyperthermia and hyponatremia are leading causes of severe harm with MDMA‑like drugs. Take breaks from dancing/heat, and sip isotonic fluids (roughly up to ~500 ml per hour max; do not overhydrate). Seek urgent care for confusion, severe agitation, very high temperature, or seizures.

• First‑line ED management of stimulant/empathogen toxicity uses rapid external cooling for hyperthermia plus IV benzodiazepines (e.g., lorazepam 2 mg or equivalent) for agitation; these principles apply to MDMA‑like benzofurans as well.

• Avoid MAOIs, DXM, tramadol, PMA/PMMA and poly‑stimulant combos: these elevate serotonin syndrome, seizure, and overheating risk. Use TripSit’s combination chart as a cross‑reference when evaluating combos.

• 5‑HT2B activation is linked to valvular heart disease with serotonergic agonists (e.g., fenfluramine; MDMA shows some activity). Benzofurans 5‑/6‑APB show 5‑HT2B agonism in vitro; by structural analogy, 5‑MAPB may share this liability. Space uses widely (≥4–6 weeks) and minimize lifetime exposure as a prudent precaution. [Mechanistic and clinical context for 5‑HT2B–valvulopathy risk.]

• Standard immunoassay drug screens typically do not test for 5‑MAPB unless targeted; detection windows are unknown. Do not rely on this to avoid detection.

• IM/IV routes increase infection, vascular, and dosing risks without clear benefit; if someone insists on injecting any drug, harm‑reduction groups stress sterile equipment and low‑dead‑space syringes—but oral remains the least risky ROA for this class.

• Consider volumetric dosing and accurate milligram scales to avoid measurement error, especially for non‑oral routes or boosters.

• Drug checking programs have repeatedly found unexpected contents and mislabeling in NPS; where available, use lab services for confirmation.

• Cannabis can either smooth or destabilize the experience; several users report increased confusion/anxiety when combined during peaks—approach cautiously.